Ara-290, Cibinetide

ARA-290 is also called cibinetide. It was tested for small nerve fibre loss linked to sarcoidosis.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

The most useful checked trial separates measured nerve fibres from pain relief. They are not the same outcome.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Open the pathway notes below. A biological pathway is a possible chain of events in the body. The grade states where it was tested.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Each proposed mechanism

Repair receptor research

The trial describes cibinetide as an innate repair receptor agonist. Its biological target does not by itself prove that all nerves are repaired.

Evidence note: Described biology; not directly tested by this outcome trial

Sources

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Go deeper

Repair receptor research Described biology; not directly tested by this outcome trial

The trial describes cibinetide as an innate repair receptor agonist. Its biological target does not by itself prove that all nerves are repaired.

Sources

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Open the outcome notes. They show the tested condition and what was measured. A positive marker, a mouse result and a clinical benefit are different things.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Read this before you read a benefit into it

Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.

Human research found for this product

Cibinetide: sarcoidosis small nerve fibre trial A

Proof grade	A
Design	Randomised placebo-controlled phase 2b
People or model	People with sarcoidosis-related small nerve fibre loss and neuropathic pain
Number	64
Outcome measured	Corneal nerve fibre area at day 28
Result	The 4 mg group had a placebo-corrected gain of 697 square micrometres (95% CI 159-1236; P=0.012). The 1 and 8 mg groups did not show a clear difference. The reported pain comparison for the 4 mg subgroup was not statistically significant (P=0.157).
Route in the study	Route not confirmed from abstract
Duration	28 days
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Go deeper

Corneal nerve fibre area at day 28 A

A: Tested in People with sarcoidosis-related small nerve fibre loss and neuropathic pain. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Overall state of the evidence

Status: scoped-human-evidence

The nerve measurement is a surrogate, a stand-in measure. It is not proof of relief for every cause of neuropathy. The pain result must not be called a proven reduction.

Risk summary

The nerve measurement is a surrogate, a stand-in measure. It is not proof of relief for every cause of neuropathy. The pain result must not be called a proven reduction.

What is still open

• Supplier identity and batch match have not been verified
• Full-text systematic review and complete interactions are not finished
• Cause of nerve symptoms
• Baseline pain and function
• Exact product
• Full adverse-event and route data

Checks a reviewer must finish first

• Cause of nerve symptoms
• Baseline pain and function
• Exact product
• Full adverse-event and route data

How to read the proof grades

• A: Controlled human trial. Note whether randomisation and blinding were confirmed.
• B: Small uncontrolled human study or chart review.
• C: Whole-animal intervention.
• D: Cell or other laboratory study.
• E: User reports. Kept separate and never substituted for a measured outcome.
• ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.

Go deeper

How to read the proof Open the checked detail

A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.

A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.

Sources

• Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)

Open questions Open the checked detail

Supplier identity and batch match have not been verified

Full-text systematic review and complete interactions are not finished

Cause of nerve symptoms

Baseline pain and function

Exact product

Full adverse-event and route data

Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Studies named in this tile

Personal regimen	Not set. A study regimen is not a personal instruction.

What people report

No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.

Each human record

Cibinetide: sarcoidosis small nerve fibre trial A

Proof grade	A
Design	Randomised placebo-controlled phase 2b
People or model	People with sarcoidosis-related small nerve fibre loss and neuropathic pain
Number	64
Outcome measured	Corneal nerve fibre area at day 28
Result	The 4 mg group had a placebo-corrected gain of 697 square micrometres (95% CI 159-1236; P=0.012). The 1 and 8 mg groups did not show a clear difference. The reported pain comparison for the 4 mg subgroup was not statistically significant (P=0.157).
Route in the study	Route not confirmed from abstract
Duration	28 days
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.

The nerve measurement is a surrogate, a stand-in measure. It is not proof of relief for every cause of neuropathy. The pain result must not be called a proven reduction.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Route needs full-method confirmation before an administration description is added. Research routes describe what was studied. They are not a client administration guide.

Sources for this tile

• Cibinetide: sarcoidosis small nerve fibre trial (Culver and colleagues · 2017 · Published abstract · checked 2026-10-08)

Routes seen in the research

• Route not confirmed from abstract

Dose and cycle fields in the library

These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.